lixisenatide trade name lyxumia european union adlyxin us manufactured sanofi oncedaily injectable receptor agonist treatment type diabetes lixisenatide used adjunct diet exercise treat type european union use limited complementing insulin unclear affect persons risk provided autoinjector containing fourteen doses injected lixisenatide used people problems stomach lixisenatide delays emptying stomach may change quickly drugs taken mouth take results research work done mcclean pl et al demonstrated receptor agonists liraglutide lixisenatide market treatments type diabetes show promise potential drug treatments alzheimer disease ad lixisenatide equally effective lower dose compared liraglutide measured parameters ten weeks daily intraperitoneal injections liraglutide nmolkg lixisenatide nmolkg saline mice age amyloid plaques already formed analyzing synaptic plasticity hippocampus ltp strongly increased mice either drug effectiveness accomplished lixisenatide reduction synapse numbers seen mice prevented two drugs amyloid plaque load densecore congo red positive plaque load cortex reduced drugs doses chronic inflammation response microglial activation also reduced cai hy et al demonstrated study lixisenatide could reduce amyloid plaques neurofibrillary tangles neuroinflammation hippocampi female mice activation pkacreb signaling pathway inhibition might important mechanisms neuroprotective function lixisenatide lixisenatide might potential developed novel therapy liu wet al found interesting results comparing nmolkg liraglutide nmolkg lixisenatide nmolkg found showed protective effects dose chosen liraglutide lixisenatide showed effects preventing mptpinduced motor impairment rotarod openfield locomotion catalepsy test reduction tyrosine hydroxylase th levels dopamine synthesis substantia nigra basal ganglia reduction proapoptotic signaling molecule bax increase antiapoptotic signaling molecule bcell previous results demonstrate liraglutide lixisenatide superior drugs show promise novel treatment parkinson another study done kerry hunter et al profiled receptor agonists liraglutide lixisenatide kinetics crossing blood brain barrier bbb activation measuring camp levels physiological effects brain neuronal stem cell proliferation neurogenesis evaluated drugs able cross bbb lixisenatide crossed bbb doses tested nmolkg ip measured min postinjection nmolkg ip h postinjection lixisenatide also enhanced neurogenesis brain liraglutide crossed bbb nmolkg ip increase detectable nmolkg ip min postinjection nmolkg ip h postinjection liraglutide lixisenatide enhanced camp levels brain lixisenatide effective previous results suggest novel incretin analogues cross bbb showing physiological activity neurogenesis brain makes good candidates used treatment neurodegenerative cases people anaphylactic reactions lixisenatide cases drug caused use insulin sulfonylurea may cause cases people kidney disease acute kidney injury people existing kidney disease condition gotten lixisenatide peptide people develop immune response eventually make drug ineffective people developed antibodies lixisenatide tend inflammation injection least people nausea vomiting diarrhea headache dizziness taking lixisenatide member class glucagonlike receptor agonist drugs activates receptor hormone helps pancreatic beta cells secrete insulin response high blood sugar works like normal hormone insulin secreted blood sugar high like also slows gastric lixisenatide peptide made amino acids amide group c described heloderma meaning derived first amino acids sequence peptide isolated gila monster venom omitting proline position adding six lysine residues complete sequence created zealand pharma zealand licensed sanofi developed lixisenatide approved european commission february sanofi submitted nda us accepted review us fda february discussions fda cardiovascular safety data included package starting fda required stronger cv safety data new antidiabetes drugs following controversy around risks sanofi decided withdraw nda wait results phase iii study scheduled completed drug first agonist could taken day sales projections per year sanofi resubmitted application fda accepted september time sanofi lost lead field antidiabetic drugs novo lixisenatide received fda approval july zealand sanofi extended license agreement allow sanofi develop combination therapy lixisenatide insulin glargine sanofis best selling drug time sales around billion sanofi planned start phase iii trial sanofi submitted nda december combination called lixilan considered endocrinologic metabolic drugs advisory fda committee considering lixisenatide single may vote several members committee expressing reservations sanofis plans offer two pens different ratios insulin glargine lixisenatide one people never taken insulin one people also concern handle dosing switching people single drug regimen combination august fda told sanofi delaying final decision three months asked sanofi data people used delivery patent protection lixisenatide expired httpsenwikipediaorgwikilixisenatide